Seattle Genetics, Inc (NASDAQ:SGEN) Impressed After Receiving Positive Data For Adcetris

Seattle Genetics, Inc (NASDAQ:SGEN) and Takeda Pharmaceutical Company Limited are the main newsmakers today after they announce positive results in regards to the phase III study, ECHLEON 1 study. It was set up in a bid to evaluate Adcetris (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in the different persons diagnosed with […]